Biogen Inc (BIIB)-医療機器分野:企業M&A・提携分析

◆英語タイトル:Biogen Inc (BIIB) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8011220
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月22日
◆ページ数:75
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Biogen Inc (Biogen) is a global biotechnology company that manufactures and markets drugs for the treatment of neurodegenerative diseases and rare and autoimmune disorders. Its marketed products include Avonex (interferon beta-1a), Tysabri (natalizumab), Tecfidera (dimethyl fumarate), Zinbryta (daclizumab), Fampyra (prolonged-release fampridine tablets) and Plegridy (peginterferon beta-1a) for the treatment of multiple sclerosis (MS); Spinraza (nusinersen) for spinal muscular atrophy (SMA); and Fumaderm (fumaric acid esters) for plaque psoriasis. The company also offers biosimilars through its joint venture, Samsung Bioepis. It has several products candidates targeting various indications such as MS, Parkinson’s disease, Alzheimer’s disease and Non-Hodgkin’s lymphoma, among others. The company sells its products through direct sales forces, marketing groups and distributors in the Americas, Europe, Asia and Other territories. Biogen is headquartered in Cambridge, Massachusetts, the US.

Biogen Inc (BIIB) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Biogen Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Biogen Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Biogen Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Biogen Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
Biogen Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Biogen Inc, Medical Equipment, Deal Details 11
Partnerships 11
Biogen Expands Licensing Agreement with Absorption Systems 11
Siemens Healthcare Enters into Co-Development Agreement with Biogen 12
Enigma Biomedical Enters into Research Agreement with Biogen and Merck 13
AC Immune Enters into Partnership with Biogen 14
Oklahoma Medical Research Foundation Enters into Research Agreement with Biogen 15
Regulus Therapeutics Enters into Agreement with Biogen Idec for microRNA Biomarkers 16
Regulus Therapeutics Amends Agreement With Biogen Idec 17
Regulus Therapeutics Enters Into An Agreement With Biogen Idec For Biomarkers 18
Orasi Medical Enters Into An Agreement With Biogen Idec 19
Debt Offering 20
Biogen Raises USD1.5 Billion in Public Offering of 2.9% Notes Due 2020 20
Biogen Raises USD1.75 Billion in Public Offering of 5.2% Notes Due 2045 22
Biogen Raises USD1.75 Billion in Public Offering of 4.05% Notes Due 2025 24
Biogen Raises USD1 Billion in Public Offering of 3.625% Notes Due 2022 26
Acquisition 28
Bristol-Myers Rumored To Acquire Biogen Idec 28
Biogen Inc – Key Competitors 29
Biogen Inc – Key Employees 30
Biogen Inc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Joint Venture 36
Recent Developments 37
Financial Announcements 37
Oct 24, 2017: Biogen Reports Quarterly Revenues of $3.1 Billion 37
Jul 25, 2017: Biogen Reports Record Quarterly Revenues of $3.1 Billion, Raises Full Year Revenue Guidance 39
Apr 25, 2017: Biogen Reports First Quarter 2017 Revenues of $2.8 Billion 42
Jan 26, 2017: Biogen Reports 2016 Revenues of $11.4 Billion 44
Oct 26, 2016: Biogen Reports Record Third Quarter 2016 Revenues of $3.0 Billion 46
Jul 21, 2016: Biogen Reports Second Quarter 2016 Revenues of $2.9 Billion 48
Corporate Communications 51
Dec 04, 2017: Biogen Appoints Mark Hernon as SVP, Chief Information Officer 51
Nov 21, 2017: Biogen Appoints Jeff Capello as Executive Vice President and Chief Financial Officer 52
Nov 02, 2017: Biogen Appoints Chirfi Guindo as Executive Vice President and Head of Global Marketing, Market Access and Customer Innovation 53
Sep 12, 2017: Biogen Appoints Sanjay Jariwala as SVP, Worldwide Medical 54
Jul 31, 2017: Biogen Appoints Anabella Villalobos Senior Vice President, Biotherapeutic & Medicinal Sciences 55
Jul 24, 2017: Alisha A. Alaimo Appointed SVP of Biogen’s US Therapeutic Operations 56
Jul 10, 2017: Biogen Appoints Amy Chevalier Efantis Vice President of Government Affairs 57
Jun 28, 2017: Biogen Appoints Catherine Steele Senior Vice President of Corporate Affairs 58
Jun 20, 2017: Biogen Appoints Ginger Gregory Executive Vice President, Chief Human Resources Officer 59
Jun 14, 2017: Jean-Paul Kress Appointed EVP and President, International and Head of Global Therapeutic Operations 60
Jun 13, 2017: Biogen Announces Management Change 61
Mar 16, 2017: Biogen Appoints Anirvan Ghosh Senior Vice President, Research and Early Development 62
Dec 19, 2016: Biogen Names Michel Vounatsos Chief Executive Officer 63
Nov 15, 2016: Biogen announces management changes 64
Jun 21, 2016: Biogen Names Paul McKenzie Executive Vice President, Pharmaceutical Operations & Technology 65
Legal and Regulatory 66
Sep 05, 2017: Forward Pharma Files Opening Brief in the Appeal of the U.S. Patent Interference to the Federal Circuit 66
May 01, 2017: Forward Pharma Further Aligns Cost Structure with Focus Following Settlement and License Agreement 67
Feb 09, 2017: Forward Pharma Received US$ 1.25bn pursuant to Settlement and License Agreement with Biogen 68
Jan 12, 2017: Biogen Spin-off Bioverativ Commences When-Issued Trading of Common Stock 69
Other Significant Developments 70
Jun 14, 2017: Accenture Labs and 1QBit Work with Biogen to Apply Quantum Computing to Accelerate Drug Discovery 70
Dec 22, 2016: Biogen Announces Effectiveness of Bioverativ Form 10 Registration Statement 71
Nov 30, 2016: Sangamo’s Genome Editing Program for Hemoglobinopathies to Transfer to Biogen’s Spin-Off Bioverativ 72
Jul 22, 2016: Medidata Cloud Technology Selected to Support Biogen Clinical Trials 73
Jun 28, 2016: Biogen Selects Cognizant’s SmartTrials Platform 74
Appendix 75
Methodology 75
About GlobalData 75
Contact Us 75
Disclaimer 75

List of Tables
Biogen Inc, Medical Equipment, Key Facts, 2016 2
Biogen Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Biogen Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Biogen Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Biogen Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Biogen Inc, Deals By Market, 2011 to YTD 2017 9
Biogen Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Biogen Expands Licensing Agreement with Absorption Systems 11
Siemens Healthcare Enters into Co-Development Agreement with Biogen 12
Enigma Biomedical Enters into Research Agreement with Biogen and Merck 13
AC Immune Enters into Partnership with Biogen 14
Oklahoma Medical Research Foundation Enters into Research Agreement with Biogen 15
Regulus Therapeutics Enters into Agreement with Biogen Idec for microRNA Biomarkers 16
Regulus Therapeutics Amends Agreement With Biogen Idec 17
Regulus Therapeutics Enters Into An Agreement With Biogen Idec For Biomarkers 18
Orasi Medical Enters Into An Agreement With Biogen Idec 19
Biogen Raises USD1.5 Billion in Public Offering of 2.9% Notes Due 2020 20
Biogen Raises USD1.75 Billion in Public Offering of 5.2% Notes Due 2045 22
Biogen Raises USD1.75 Billion in Public Offering of 4.05% Notes Due 2025 24
Biogen Raises USD1 Billion in Public Offering of 3.625% Notes Due 2022 26
Bristol-Myers Rumored To Acquire Biogen Idec 28
Biogen Inc, Key Competitors 29
Biogen Inc, Key Employees 30
Biogen Inc, Other Locations 32
Biogen Inc, Subsidiaries 32
Biogen Inc, Joint Venture 36

★海外企業調査レポート[Biogen Inc (BIIB)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Fanhua Inc:企業のM&A・事業提携・投資動向
    Fanhua Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Fanhua Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • Pact Group Holdings Ltd:企業の戦略・SWOT・財務情報
    Pact Group Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Pact Group Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Rexahn Pharmaceuticals Inc (RNN):企業の財務・戦略的SWOT分析
    Summary Rexahn Pharmaceuticals Inc (Rexahn Pharmaceuticals), formerly Corporate Road Show.com Inc is a biopharmaceutical company that develops and commercializes therapeutics for the treatment of cancer. The company develops anti-cancer drug candidates including Archexin that is intended for the tre …
  • Realty Income Corporation:企業のM&A・事業提携・投資動向
    Realty Income Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Realty Income Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisi …
  • Mercury NZ:企業の戦略・SWOT・財務情報
    Mercury NZ - Strategy, SWOT and Corporate Finance Report Summary Mercury NZ - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • ROHM Co Ltd (6963):企業の財務・戦略的SWOT分析
    ROHM Co Ltd (6963) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Lockton, Inc:企業の戦略・SWOT・財務情報
    Lockton, Inc - Strategy, SWOT and Corporate Finance Report Summary Lockton, Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Vestas Wind Systems AS (VWS):企業の財務・戦略的SWOT分析
    Vestas Wind Systems AS (VWS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Msig Holdings (Asia) Pte. Ltd.
    Msig Holdings (Asia) Pte. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Msig Holdings (Asia) Pte. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • University of Massachusetts Medical School:企業のM&A・事業提携・投資動向
    University of Massachusetts Medical School - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's University of Massachusetts Medical School Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detai …
  • Dermira Inc (DERM)-医療機器分野:企業M&A・提携分析
    Summary Dermira Inc (Dermira) is a bio-pharmaceutical company which concentrates on the development and commercialization of novel therapies for the treatment of chronic skin conditions. The company concentrates on developing drugs for the treatment of diseases such as psoriasis, hyperhidrosis, atop …
  • Modus Therapeutics Holding AB-製薬・医療分野:企業M&A・提携分析
    Summary Modus Therapeutics Holding AB (Modus), formerly known as Dilaforette Holding AB, is a biotechnology company that focuses on the development of sevuparin, a proprietary polysaccharide drug for the treatment of sickle cell disease (SCD). Modus Therapeutics Holding AB - Pharmaceuticals & Health …
  • Xtract Resources Plc (XTR):企業の財務・戦略的SWOT分析
    Summary Xtract Resources Plc (Xtract Resources), formerly Xtract Energy plc is a mining and mineral exploration and development company that offers mineral resources. The company acquires, explores, manages, operates, produces, mines, extracts, and develops gold and mineral resource deposit properti …
  • Western & Southern Financial Group, Inc.:戦略・SWOT・企業財務分析
    Western & Southern Financial Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Western & Southern Financial Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Western Farmers Electric Cooperative:企業の発電所・SWOT分析2018
    Western Farmers Electric Cooperative - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information …
  • Shermco Industries, Inc.:電力:M&Aディール及び事業提携情報
    Summary Shermco Industries, Inc. (Shermco), a member of the GFI Energy Group of Oaktree Capital Management LP, is an independent service company that provides electrical maintenance, repair, testing, and analysis services for electrical systems and equipment. It also offers industrial contracting, u …
  • China Southern Airlines Company Limited:企業の戦略・SWOT・財務情報
    China Southern Airlines Company Limited - Strategy, SWOT and Corporate Finance Report Summary China Southern Airlines Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • AstraZeneca KK-製薬・医療分野:企業M&A・提携分析
    Summary AstraZeneca KK (AstraZeneca), a subsidiary of AstraZeneca Plc is a drug company that provides prescription medicines. The company offers products such as akoreto, arimidex, iressa, inderal, casodex, crestor, and other tablets. It offers products for oncology, cardiovascular and metabolic dis …
  • EyePoint Pharmaceuticals Inc (PSDV):製薬・医療:M&Aディール及び事業提携情報
    Summary EyePoint Pharmaceuticals Inc (EyePoint), formerly pSivida Corp, is a biopharmaceutical company that provides development of miniaturized, sustained-release drug delivery products and technologies. The company offers products such as iluvien, retisert and durasert, among others. Its durasert …
  • bluebird bio Inc (BLUE):企業の財務・戦略的SWOT分析
    bluebird bio Inc (BLUE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆